Anti-PD-1 antibodies / PD-1 inhibitors + Anti-VEGF-A antibodies / VEGF-A antagonists + Chemotherapy (CT) & Ovarian cancer

• The triplet of Anti-PD-1 antibodies / PD-1 inhibitors + Anti-VEGF-A antibodies / VEGF-A antagonists + Chemotherapy (CT) in ovarian cancer has limited early-phase clinical evidence.


• It is not a standard regimen for ovarian cancer currently.


• Stronger data exist for PD-1/VEGF combinations without chemotherapy.


• Bevacizumab plus chemotherapy without PD-1 blockade also has stronger data.

see also:
Bevacizumab + Paclitaxel + Pembrolizumab & Ovarian cancer
[Bevacizumab + Paclitaxel + Pembrolizumab/berahyaluronidase alfa & Ovarian Cancer](brain://0Rs-ltxiFk6_IteqfqSFEg/BevacizumabPaclitaxelPe…